- Home
- SMX vs LYEL Comparison
SMX vs LYEL Comparison
Compare SMX & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SMX | LYEL |
|---|---|---|
| Founded | N/A | 2018 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 490.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SMX | LYEL |
|---|---|---|
| Price | $28.74 | $25.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 932.7K | 91.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $61,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.75 | $0.39 |
| 52 Week High | $490.00 | $45.00 |
Technical Indicators
Market Signals| Indicator | SMX | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 56.89 |
| Support Level | $1.07 | $21.27 |
| Resistance Level | $62.98 | $27.30 |
| Average True Range (ATR) | 4.64 | 2.01 |
| MACD | 0.31 | 0.19 |
| Stochastic Oscillator | 1.96 | 84.87 |
Price Performance
Historical ComparisonAbout SMX SMX (Security Matters) Public Limited Company
SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.